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Introduction
In recent years, traditional treatment modalities have
been approaching therapeutic plateau in almost all
fields of oncology. In order to improve treatment out-
comes, large efforts were undertaken to identify novel
therapeutic targets and robust laboratory tests that
could identify patients with tumors that are sensitive to
particular therapies. We now have a plethora of novel
targeted therapies which have modest activity in unse-
lected patient populations but may be very effective in
individual patients with particular molecular charac-
teristics of their tumors. Despite rapid improvements
in cancer genomic and proteomic technologies,
immunohistochemistry remains the most commonly
used technique in pathology laboratories worldwide,
and is widely applicable for identification of molecu-
lar markers of cancer diagnosis, prognosis and predic-
tion of treatment efficacy. 
Lung cancer is the leading cause of cancer-related
deaths worldwide [1]. Approximately 80% of the lung
cancer patients are diagnosed with non-small-cell his-
tological types: squamous cell carcinoma, adenocarci-
noma or large cell carcinoma; the remaining 20% of
patients are diagnosed with small cell lung cancer.
Individualization of treatment strategy is now in the
focus of lung cancer research and some of the discov-
ered tests are used in phase II-III clinical trials or in
clinical practice. These tests are sought to better define
patient prognosis (particularly important after surgical
resection), to predict the treatment benefit in the adju-
vant (post-surgical) setting, as well as in the first or
second line therapy of advanced disease. Prognostic
tests are associated with patient's outcome regardless
of treatment administered, whereas predictive tests
identify subsets of patients who will or will not bene-
fit from administered therapies. In advanced disease
the benefit of treatment can be quantified as a
response, durable stable disease, or more importantly,
prolongation of progression-free or overall survival.
Some assays may provide both prognostic and predic-
tive information, as for example tumor estrogen recep-
tor positivity is a weak positive prognostic marker and
a strong predictive marker for the benefit of hormonal
therapy in breast cancer. Predictive value of the mark-
er can be distinguished from its prognostic value only
through analysis of samples and outcome data from
controlled phase III clinical trials with the proper con-
trol group of patients. In such studies, predictive value
of the test for survival benefit can be assessed by com-
parison of hazard ratios in marker-positive versus
marker-negative subsets of patients. The predictive
value of the test is indicated by the difference between
these hazard ratios, which can be formally compared
by the treatment-by-marker interaction test. It is also
important to emphasize that single-arm or cohort stud-
ies are inadequate to distinguish between prognostic
and predictive value of the marker, and thus results of
such studies should be interpreted with caution. In this
review, we aimed to summarize the current use of
quantitative immunohistochemistry markers as prog-
nostic or predictive tools in lung cancer research. 
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Quantitative measurement of the observed
immunostaining (protein level) by a pathologist is
done with numerous scales and there is no consensus
which scale is better or more practical. Often, percent-
age of cells with positive staining of any intensity is
recorded. To account for the protein abundance, the
percentage of cells with positive staining is multiplied
by the staining intensity (graded from 0 to 3 or from 0
to 4) to give the staining index (ranging from 0 to 300
or from 0 to 400, respectively) [2,3]. In other systems,
the staining index is composed of percentage of posi-
tive cells binned into categories and multiplied by
staining intensity (0 to 3 or 0 to 4 scale) [4]. In all clas-
sifications, it is very important to note whether the
staining is present in the cell membrane, cytoplasm, or
nucleus, or in more than one of these cell compart-
ments. Precise quantification of the protein level by
the pathologist is aimed to provide accurate data to be
analyzed with patient outcome and to select the best
prognostic or predictive cut-off points of the test. For
example, quantification of epidermal growth factor
receptor (EGFR) protein by immunohistochemistry for
prediction of therapeutic benefit from EGFR inhibitors
was performed in two phase III clinical trials, BR.21
and ISEL. The trials were designed to assess the effi-
cacy of erlotinib or gefitinib versus placebo in non-
small-cell lung cancer (NSCLC) patients who failed at
least one line of chemotherapy [5,6]. With pre-defined
cut-off point of 10% of positive cells of any staining
intensity, lack of EGFR protein staining was a predic-
tor of lack of benefit from theses agents [7,8]. In both
studies, precise quantitative data on EGFR protein
expression were collected, allowing for exploratory
analyses aimed to determine the cut-off point of EGFR
positivity that provides best predictive value [3,9]. The
results of these studies were consistent and indicated
that indeed pre-specified cut-off point of 10% of cells
with any staining had the best predictive power, as
measured by hazard ratios. 
Quantitative evaluation of protein levels in tumor
samples presents several challenges, including techni-
cal issues related to immunohistochemistry procedure
and subjectivity of assessment. Small tumor speci-
mens, such as those frequently obtained in advanced
lung cancer, may not be representative of the tumor
due to its significant heterogeneity [10]. Protein
expression in primary versus metastatic tumor sites
may vary by as much as 30%, and clinical significance
of this difference is unknown. Small samples are more
susceptible to artifacts, such as the "edge effect" with
non-specific staining observed in the very edge of the
specimen. Choice of the primary antibody and antigen
retrieval conditions are of great importance. In our
recent study, we obtained completely different results
for two tested primary antibodies against insulin-like
growth factor-1 receptor (IGF1R) in NSCLC primary
tumor samples. We confirmed the association of
IGF1R protein level with IGF1R mRNA expression
measurement for one but not for the other antibody,
which suggests that one of these antibodies does not
detect its target protein [Dziadziuszko et al., submit-
ted]. Ideally, specificity of the primary antibody
against the target protein should be confirmed by other
techniques, such as Western blot. Positive controls
(specimens with known expression of the target pro-
tein) and negative controls should always be included
in the procedure. To account for the variability of some
of the above problems, automated staining procedures
were developed and are in use in many laboratories. 
The subjectivity of quantitative measurement of
protein levels remains an important consideration. It is
generally recommended that at least two pathologists
should independently score each specimen, with the
consensus meeting to solve significant discrepancies.
The concordance between the readings of two (or
more) observers provides a good estimate of the
robustness of the scoring system and provision of such
information is highly recommended in research proto-
cols and publications. Automated scoring systems are
in development to avoid inter-observer variability and
facilitate the quantification. Such systems are based on
optical density measurements [11] or the quantifica-
tion of fluorescence measurements from the secondary
antibody [12]. Before these systems become widely
accepted, validation studies with standard immunohis-
tochemistry scoring methods are needed. 
Quantitative immunohistochemistry studies as
prognostic tests
The information on prognosis of patients who under-
went curative pulmonary resection for NSCLC is
based on pathological TNM staging system and other
criteria, such as vessel invasion or patient's comorbid-
ity indices. This information is not precise, as for
example up to 30-40% of patients with very early stage
NSCLC will later present with local or distant relapse
and die from their disease [13]. Thus, novel prognostic
indices are needed to better stratify patients who are
likely to relapse following surgery alone. A number of
reports proposed "molecular staging" using several
immunohistochemical markers together with clinical
parameters to refine prognosis of early stage NSCLC.
Kwiatkowski et al. [14] analyzed the expression of
several proteins in primary tumors from 244 surgical-
ly treated stage I NSCLC patients. After elimination of
insignificant markers, the authors included p53 stain-
ing and H-ras p21 staining together with other features
(K-ras mutations, mucin producing tumors, lymphatic
invasion and tumor diameter of 4 cm or more) in their
final prognostic model, which separated stage I
NSCLC patients into three markedly different prog-
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nostic groups [14]. In a study of 408 consecutive stage
I patients, D'Amico et al. proposed erbB-2, p53, CD-
44 and factor VIII protein expression as independent
prognostic markers stratifying patients who have
excellent or poor outcome [15]. Despite demonstration
of additional prognostic information, these systems
were not validated in other patient cohorts nor widely
accepted for the use in the practice. Currently devel-
oped molecular prognostic models in operable NSCLC
explore other technologies, which are mainly based on
gene or micro-RNA expression quantification using
gene array or quantitative RT-PCR platforms [16-20].
The main advantages of these technologies include
wide dynamic range of gene expression quantification
and automated simultaneous measurement of up to
hundreds of genes in one reaction. The most promising
molecular prognostic signatures are now tested in
prospective clinical trials in early operable NSCLC to
answer the question of whether patients in the poor
risk category may benefit from adjuvant chemothera-
py. Due to the above mentioned advantages of gene
expression evaluation, it is unlikely that multiple
immunohistochemistry based markers will find their
practical application to refine prognosis of operable
NSCLC patients. Nevertheless, it is important to know
the prognostic value of any immunohistochemical
marker evaluated for other purposes in tumor samples
of NSCLC patients. 
Quantitative immunohistochemistry studies as
predictive tests
Chemotherapy represents current standard of care in
advanced unresectable or metastatic NSCLC and as an
adjunct to surgery in stage II-IIIA patients. In both set-
tings, the survival benefit from this treatment is rela-
tively modest (survival hazard ratio in the order of 0,8)
at the expense of significant toxicity and costs. 
Sensitivity to chemotherapy appears to inversely
correlate with the activity of several enzymes respon-
sible for the DNA damage repair. Low level of exci-
sion repair cross-complementing-1 (ERCC1), a rate
limiting enzyme of nucleotide excision repair pathway,
is associated with sensitivity to alkylating agents in
vitro and in samples from patients treated with plat-
inum-based chemotherapy [21]. Low level of human
MutS homolog 2 (MSH2), a mismatch repair enzyme,
was linked with sensitivity to cisplatin [22]. Low
expression of regulatory subunit of ribonucleotide
reductase (RRM1) was associated with sensitivity to
gemcitabine in cell lines as well as in a clinical setting
[23]. Low expression of BRCA1 seems to predict sen-
sitivity to cisplatin [24], whereas high expression may
be associated with sensitivity to antimicrotubule drugs
such as taxanes and vinorelbine [25]. Many of the
studies with predictive markers for chemotherapy
were done with quantitative immunohistochemistry,
whereas other studies evaluated gene expression with
quantitative RT-PCR in fresh-frozen or paraffin-
embedded tumor samples. Tests based on both plat-
forms are being explored in prospective clinical stud-
ies aiming at individualizing chemotherapy according
to the sensitivity profiles of the tumors. 
Several markers have shown promising predictive
value in the adjuvant chemotherapy. Immunohisto-
chemical analysis of ERCC1 expression in tumor sam-
ples from participants of the IALT study investigating
the role of postoperative chemotherapy indicated that
the survival benefit from chemotherapy was confined
to protein-negative subset (adjusted hazard ratio,
HR=0.65 as compared with surgery alone) in contrast
to the protein-positive subset of patients (HR=1.14; p-
value for interaction with treatment =0.009) [4]. Of
several cell-cycle regulatory proteins studied, tumoral
expression of p27Kip1 was predictive for survival ben-
efit in patients treated with adjuvant chemotherapy in
the IALT trial [26]. Low protein level indicated the
subset of patients who benefited from treatment
(adjusted HR=0.66) and high level – those who did not
(adjusted HR=1.09, p-value for interaction = 0.02).
P27Kip1 is a member of cyclin-dependent kinase
inhibitory proteins preventing transition from G1 to S
phase of the cell cycle. High levels of the protein result
in accumulation of cells in G1 phase, which is rela-
tively insensitive to phase-specific chemotherapy, and
protection from apoptosis. A recent report presented at
2009 annual American Society of Clinical Oncology
meeting showed that negative immunostaining for
MSH2 protein is associated with sensitivity to
chemotherapy (adjusted HR=0.76) whereas positive
immunostaining associated with resistance (adjusted
HR=1.12, p-value for interaction= 0.06) [27]. A subset
analysis of JBR.10 study testing the efficacy of adju-
vant cisplatin and vinorelbine showed that patients
with p53-positive tumors by immunohistochemistry
achieved survival benefit from chemotherapy
(HR=0.54) as opposed to patients with p53-negative
tumors (HR=1.40, interaction test p=0.02) [28].
Untreated p53-positive patients had shorter survival
than p53-negative patients, confirming previous obser-
vations of negative prognostic value of p53 expression
in NSCLC. The predictive value of these and other
markers by immunohistochemistry for adjuvant
chemotherapy in NSCLC is presented in table 1.
Most of the predictive markers for chemotherapy
also carry prognostic information in early-stage
NSCLC. High levels of ERCC1 or RRM1 (indicative
of chemoresistance to cisplatin and gemcitabine
respectively) are associated with better prognosis of
surgically-treated patients through increased genomic
stability of the tumor cells [12]. It appears that the
analysis of these markers would indicate the subset of
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patients with relatively good post-surgical outcome in
whom adjuvant chemotherapy would be unnecessary
and ineffective. Prospective clinical studies to test this
hypothesis are ongoing in Europe (TASTE phase II
feasibility study, led by the French Lung Cancer Coop-
erative group) and in North America (Southwest
Oncology Group SWOG 0720 phase II trial).
Conclusions
Quantitative immunohistochemistry remains a very
important and practical platform and is being evaluat-
ed in multiple clinical trials in lung cancer with hopes
to improve patient outcome and avoid unnecessary
therapies. Importantly, these tests are relatively unex-
pensive and easily applicable in virtually all pathology
departments. Test standardization and the choice of
optimal cut-off points to define a positive result remain
the most important issues before such tests are widely
adopted. Currently initiated controlled phase III ran-
domized clinical trials should include properly defined
translational part. Quantitative immunohistochemical
assessment of putative prognostic and/or predictive
markers remains essential component of these trials.
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